Nasdaq
$4.05▲ 0.37%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $75.0MShares out 18.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 10.15Regular26.10.15 23:278-KKey event#●●●#●●●
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals updated its corporate presentation on October 15, 2026, detailing clinical progress and upcoming milestones for its key assets, CRB-701 and CRB-913. As of June 30, 2026, the company reported approximately $118 million in cash, cash equivalents, and investments, with 18.7 million common shares issued and outstanding (approximately 22.4 million on a fully diluted basis).…more
$4.05+0.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30After-hours26.10.01 05:57SCHEDULE 13GOwnership
Corbus Pharmaceuticals Holdings, Inc.
RA Capital Management, L.P. and its affiliates have entered into a joint filing agreement regarding their beneficial ownership of Corbus Pharmaceuticals Holdings, Inc. common stock. This agreement allows the parties to collectively file Schedule 13G and 13D statements with the SEC.…more
$4.05+0.37%vs prev closeView filingShare - 9.15After-hours26.09.16 05:594Ownership
Corbus Pharmaceuticals Holdings, Inc.
Insider Ben Yong of Corbus Pharmaceuticals Holdings, Inc. reported a change in beneficial ownership of securities as of September 14, 2026. This filing is a Form 4 statement detailing the insider's transaction.…more
$4.05+0.37%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoPre-market26.10.22 21:03#●●●#●●●
Corbus Pharmaceuticals to Present Phase 1B Data for Obesity Drug at Obesity Week 2026…more
Corbus Pharmaceuticals announced it will present late-breaking data from its Phase 1B Canyon-1 study of CRB-913 at Obesity Week 2026. This presentation serves as an update on clinical progress, with further results needed to determine long-term efficacy.…more
$4.05+0.37%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.29Pre-market26.09.29 21:05
●●●●●●●● ●●●●● ●●●●●●
Corbus Pharmaceuticals has initiated the first patient dosing in its registrational TEMPO-1 study for the oropharyngeal cancer treatment CRB-701. While this marks a milestone in clinical development, the long-term efficacy remains to be proven.…more
$4.05+0.37%vs prev closeShareBenzinga - 9.14Regular26.09.14 23:49
●●●●●●●● ●●●●● ●●●●●●
Corbus Pharmaceuticals announced significant weight loss and a favorable safety profile for its obesity drug candidate CRB-913 in a Phase 1b trial. The company plans to consult with the FDA to initiate Phase 2 trials in the first half of 2027.…more
$4.05+0.37%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report